Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $21.99 | $4.40/mg | In stock | Jul 4 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| Green Cap | Jun 2025 | 99.2% | Vanguard Laboratory | — | Unverified | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHRP-6 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Kimera Chems sell GHRP-6?
Yes — Kimera Chems currently lists GHRP-6 in 1 variant starting at $21.99 ($4.40/mg).
Is Kimera Chems's GHRP-6 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Kimera Chems's GHRP-6, with the most recent showing 99.2% purity. Kimera Chems holds an overall trust grade of C (70/100) across all 355 COAs on file.
What is Kimera Chems's trust grade for GHRP-6?
Kimera Chems has an overall Disclosed Labs trust grade of C (70/100), computed from 355 COAs across all peptides. The most recent GHRP-6 COA was issued by Vanguard Laboratory.
Where is the cheapest GHRP-6?
As of the latest data, Verified Peptides offers GHRP-6 at $1.51/mg — compare with Kimera Chems's listing at $4.40/mg. See the full GHRP-6 price comparison.
Is GHRP-6 legal to buy?
GHRP-6 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs